---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-016346"
form_type: "8-K/A"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2024-12-18T23:59:59+00:00"
generated_at: "2026-05-29T02:04:24.753009+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pharmagesic financials: $4.9M loss, $82M deficit; Dogwood provides $19.5M funding

## Summary
- Pharmagesic (Holdings) Inc. (acquired Oct 7) had $4.9M net loss in 2023; no revenue; R&D costs $3.9M.
- As of Dec 2023, stockholders' deficit was $78.7M, accumulated deficit $82.0M; total liabilities $65.1M.
- Post-Dec 2023, $63.4M due to fellow subsidiaries settled; $36.0M preferred shares exchanged for common.
- Dogwood secured $19.5M loan from CK Life Sciences to fund Pharmagesic operations through early 2026.
- Halneuron (tetrodotoxin) is the lead candidate for chemotherapy-induced neuropathic pain.

## SEC filing metadata
- accession: 0001558370-24-016346
- form_type: 8-K/A
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2024-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837024016346/0001558370-24-016346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837024016346/dwtx-20241004x8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-016346
- JSON: https://secwatch.observer/filing/0001558370-24-016346.json
- Plain text: https://secwatch.observer/filing/0001558370-24-016346.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.